دورية أكاديمية
A Vicious Cycle: In Severe and Critically Ill COVID-19 Patients.
| العنوان: | A Vicious Cycle: In Severe and Critically Ill COVID-19 Patients. |
|---|---|
| المؤلفون: | Huang P; School of Integrative Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin, China., Zuo Q; School of Integrative Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin, China., Li Y; School of Department of Clinical Training and Teaching of Traditional Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin, China., Oduro PK; State Key Laboratory of Component-Based Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin, China., Tan F; School of Integrative Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin, China., Wang Y; School of Integrative Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin, China., Liu X; School of Integrative Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin, China., Li J; School of Department of Clinical Training and Teaching of Traditional Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin, China., Wang Q; State Key Laboratory of Component-Based Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin, China., Guo F; National Health Commission of the People's Republic of China Key Laboratory of Systems Biology of Pathogens, Institute of Pathogen Biology and Center for AIDS Research, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China., Li Y; State Key Laboratory of Component-Based Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin, China., Yang L; School of Integrative Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin, China.; Research Center for Infectious Diseases, Tianjin University of Traditional Chinese Medicine, Tianjin, China. |
| المصدر: | Frontiers in immunology [Front Immunol] 2022 Jun 15; Vol. 13, pp. 930673. Date of Electronic Publication: 2022 Jun 15 (Print Publication: 2022). |
| نوع المنشور: | Journal Article; Review; Research Support, Non-U.S. Gov't |
| اللغة: | English |
| بيانات الدورية: | Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: [Lausanne : Frontiers Research Foundation] |
| مواضيع طبية MeSH: | COVID-19*, Critical Illness ; Cytokine Release Syndrome ; Cytokines/metabolism ; Humans ; Interleukin-6 ; Plasminogen Activator Inhibitor 1 ; SARS-CoV-2 ; Tumor Necrosis Factor-alpha |
| مستخلص: | The coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus, is one of the fastest-evolving viral diseases that has instigated a worldwide pandemic. Severe inflammatory syndrome and venous thrombosis are commonly noted in COVID-19 patients with severe and critical illness, contributing to the poor prognosis. Interleukin (IL)-6, a major complex inflammatory cytokine, is an independent factor in predicting the severity of COVID-19 disease in patients. IL-6 and tumor necrosis factor (TNF)-α participate in COVID-19-induced cytokine storm, causing endothelial cell damage and upregulation of plasminogen activator inhibitor-1 (PAI-1) levels. In addition, IL-6 and PAI-1 form a vicious cycle of inflammation and thrombosis, which may contribute to the poor prognosis of patients with severe COVID-19. Targeted inhibition of IL-6 and PAI-1 signal transduction appears to improve treatment outcomes in severely and critically ill COVID-19 patients suffering from cytokine storms and venous thrombosis. Motivated by studies highlighting the relationship between inflammatory cytokines and thrombosis in viral immunology, we provide an overview of the immunothrombosis and immunoinflammation vicious loop between IL-6 and PAI-1. Our goal is that understanding this ferocious circle will benefit critically ill patients with COVID-19 worldwide. Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2022 Huang, Zuo, Li, Oduro, Tan, Wang, Liu, Li, Wang, Guo, Li and Yang.) |
| References: | Clin Appl Thromb Hemost. 2021 Jan-Dec;27:1076029621999099. (PMID: 33835872) J Cardiovasc Pharmacol. 2019 Jan;73(1):22-26. (PMID: 30540689) N Engl J Med. 2020 Jul 9;383(2):120-128. (PMID: 32437596) J Cell Physiol. 2012 Feb;227(2):493-507. (PMID: 21465481) JAMA. 2020 Apr 7;323(13):1239-1242. (PMID: 32091533) Thromb Haemost. 2017 Jan 26;117(2):339-348. (PMID: 27975098) Proc Natl Acad Sci U S A. 1996 Jan 9;93(1):407-11. (PMID: 8552649) Trends Mol Med. 2007 Nov;13(11):460-9. (PMID: 18029230) Autoimmun Rev. 2020 Jul;19(7):102568. (PMID: 32376398) N Engl J Med. 2020 Mar 26;382(13):1199-1207. (PMID: 31995857) Microvasc Res. 2021 Sep;137:104188. (PMID: 34022205) Int J Antimicrob Agents. 2020 May;55(5):105954. (PMID: 32234467) Med (N Y). 2020 Dec 18;1(1):90-102. (PMID: 33294881) Diabetes Metab Res Rev. 2021 Feb;37(2):e3377. (PMID: 32588943) Clin Chim Acta. 2020 Jul;506:145-148. (PMID: 32178975) Restor Neurol Neurosci. 2021;39(2):129-137. (PMID: 33935121) J Immunol. 2010 Feb 15;184(4):2130-9. (PMID: 20083667) Life Sci. 2020 Apr 1;246:117404. (PMID: 32035128) Metab Syndr Relat Disord. 2017 Aug;15(6):269-275. (PMID: 28504921) N Engl J Med. 2020 Apr 30;382(18):1708-1720. (PMID: 32109013) Oncologist. 2018 Aug;23(8):943-947. (PMID: 29622697) J Med Virol. 2020 Jul;92(7):814-818. (PMID: 32253759) J Pharm Anal. 2020 Apr;10(2):102-108. (PMID: 32282863) Semin Thromb Hemost. 2021 Jun;47(4):451-455. (PMID: 33482678) J Clin Invest. 2011 Sep;121(9):3375-83. (PMID: 21881215) Cardiovasc Ther. 2010 Oct;28(5):e72-91. (PMID: 20626406) Front Immunol. 2021 Feb 18;12:613422. (PMID: 33679753) Nature. 1994 Mar 24;368(6469):339-42. (PMID: 8127368) Best Pract Res Clin Rheumatol. 2012 Feb;26(1):157-65. (PMID: 22424201) Trends Pharmacol Sci. 2021 Jun;42(6):431-433. (PMID: 33867130) Ann Intern Med. 2020 Sep 1;173(5):350-361. (PMID: 32422076) J Thromb Haemost. 2020 Apr;18(4):844-847. (PMID: 32073213) Cell Rep. 2018 Nov 20;25(8):2177-2191.e7. (PMID: 30463014) Science. 2020 May 1;368(6490):473-474. (PMID: 32303591) Br J Haematol. 2020 Jun;189(6):1060-1061. (PMID: 32400024) Circulation. 1994 Jul;90(1):362-8. (PMID: 8026020) Int J Exp Pathol. 2007 Dec;88(6):387-91. (PMID: 18039275) J Thromb Haemost. 2020 Sep;18(9):2215-2219. (PMID: 32668058) PLoS One. 2020 Dec 31;15(12):e0244628. (PMID: 33382773) Environ Pollut. 2021 Oct 15;287:117283. (PMID: 34426376) Redox Rep. 2020 Dec;25(1):64-69. (PMID: 32693740) J Clin Virol. 2020 Jun;127:104370. (PMID: 32344321) Thromb Haemost. 1997 Jun;77(6):1189-95. (PMID: 9241756) Atherosclerosis. 1999 Mar;143(1):81-90. (PMID: 10208482) J Lipid Res. 2007 Mar;48(3):509-12. (PMID: 17158793) Vascul Pharmacol. 2021 Apr;137:106829. (PMID: 33422689) J Exp Med. 1996 Apr 1;183(4):1399-406. (PMID: 8666898) J Hum Hypertens. 2021 Jan;35(1):4-11. (PMID: 32719447) Pulm Circ. 2020 Nov 25;10(4):2045894020966547. (PMID: 33282193) Blood. 2020 Jul 23;136(4):381-383. (PMID: 32702124) Nat Med. 2013 Jul;19(7):822-4. (PMID: 23836224) News Physiol Sci. 2002 Apr;17:56-61. (PMID: 11909993) Science. 2020 Oct 23;370(6515):408-409. (PMID: 32967937) Am J Physiol Cell Physiol. 2007 Jan;292(1):C209-15. (PMID: 16914534) Int J Clin Pract. 2011 Apr;65(4):508-13. (PMID: 21272164) N Engl J Med. 2020 Dec 10;383(24):2333-2344. (PMID: 33085857) J Clin Invest. 2014 Apr;124(4):1853-67. (PMID: 24642471) Biochem Biophys Res Commun. 2016 Aug 26;477(3):503-8. (PMID: 27317488) Inflammation. 2015 Feb;38(1):384-93. (PMID: 25342286) J Diabetes Complications. 2020 Nov;34(11):107703. (PMID: 32883567) Oncol Rep. 2020 Jul;44(1):382-392. (PMID: 32377752) J Proteome Res. 2020 Nov 6;19(11):4417-4427. (PMID: 32786691) Thromb Haemost. 2021 Nov;121(11):1417-1426. (PMID: 33634444) Cytokine X. 2020 Jun;2(2):100029. (PMID: 32421092) Microbiol Mol Biol Rev. 2012 Mar;76(1):16-32. (PMID: 22390970) Nat Immunol. 2015 May;16(5):448-57. (PMID: 25898198) Clin Chem Lab Med. 2020 Jun 25;58(7):1021-1028. (PMID: 32286245) Arthritis Rheum. 2005 Mar;52(3):818-25. (PMID: 15751095) Lancet Respir Med. 2021 Jun;9(6):643-654. (PMID: 33872590) Thromb Res. 1984 Mar 1;33(5):523-30. (PMID: 6426082) Cell Death Differ. 2020 Dec;27(12):3209-3225. (PMID: 33037393) Proc Natl Acad Sci U S A. 2020 May 19;117(20):10970-10975. (PMID: 32350134) Allergy. 2021 Feb;76(2):428-455. (PMID: 33185910) Lancet. 2020 Feb 15;395(10223):497-506. (PMID: 31986264) J Med Virol. 2020 Nov;92(11):2283-2285. (PMID: 32343429) Front Immunol. 2020 May 01;11:827. (PMID: 32425950) Proc Natl Acad Sci U S A. 2020 Sep 8;117(36):22351-22356. (PMID: 32826331) Ann Rheum Dis. 2014 Sep;73(9):1595-7. (PMID: 24833786) FASEB J. 1995 May;9(8):659-64. (PMID: 7768358) Thromb Res. 2020 Jul;191:145-147. (PMID: 32291094) Scand J Clin Lab Invest. 1985 Nov;45(7):605-10. (PMID: 3934744) Arch Med Res. 2020 May;51(4):347-348. (PMID: 32340759) Lancet. 2020 Feb 15;395(10223):507-513. (PMID: 32007143) Radiology. 2020 Apr;295(1):210-217. (PMID: 32027573) Am J Respir Cell Mol Biol. 2021 Sep;65(3):300-308. (PMID: 34003736) Thromb Res. 2020 May;189:5-12. (PMID: 32126379) Cell. 2020 Apr 16;181(2):271-280.e8. (PMID: 32142651) Respir Res. 2020 May 27;21(1):130. (PMID: 32460750) Dis Model Mech. 2021 Nov 1;14(11):. (PMID: 34542605) Viruses. 2020 Dec 26;13(1):. (PMID: 33375371) Scand J Work Environ Health. 2021 Jul 1;47(5):408-409. (PMID: 34003294) Neurosci Lett. 2021 Jan 19;743:135564. (PMID: 33352277) Mod Pathol. 2020 Jun;33(6):1007-1014. (PMID: 32291399) Arterioscler Thromb Vasc Biol. 2012 Jul;32(7):1696-706. (PMID: 22596222) Biochem J. 1994 Jun 1;300 ( Pt 2):281-90. (PMID: 8002928) Oncogene. 2012 Sep 13;31(37):4139-49. (PMID: 22158046) Chin Med J (Engl). 2020 May 5;133(9):1025-1031. (PMID: 32044814) J Thromb Thrombolysis. 2020 Aug;50(2):278-280. (PMID: 32372336) |
| فهرسة مساهمة: | Keywords: COVID-19; IL-6; PAI-1; endothelial cells; inflammatory reaction; tocilizumab; venous thrombosis |
| المشرفين على المادة: | 0 (Cytokines) 0 (Interleukin-6) 0 (Plasminogen Activator Inhibitor 1) 0 (Tumor Necrosis Factor-alpha) |
| تواريخ الأحداث: | Date Created: 20220705 Date Completed: 20220706 Latest Revision: 20220720 |
| رمز التحديث: | 20231215 |
| مُعرف محوري في PubMed: | PMC9240200 |
| DOI: | 10.3389/fimmu.2022.930673 |
| PMID: | 35784318 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1664-3224 |
|---|---|
| DOI: | 10.3389/fimmu.2022.930673 |